Lantheus Holdings to Acquire Evergreen Theragnostics for ~$1B
Shots:
- Lantheus will acquire Evergreen Theragnostics for $250M upfront plus ~$752.5M development & sales milestones related to Octevy & other assets in an all-cash transaction, with closing anticipated in H2’25 pending regulatory approvals
- The acquisition will add Evergreen’s Octevy (registrational-stage PET imaging agent for somatostatin receptor +ve NETs in adults & pediatrics) complementing Lantheus' PNT2003, a drug discovery & early-stage clinical development tech as well as early-stage oncology & radiotherapeutic candidates
- Lantheus will also acquire Evergreen’s RLT manufacturing infrastructure, revenue-generating CDMO business as well as isotope expertise, enhancing development, production & long-term growth
Ref: Lantheus Holdings | Image: Evergreen Theragnostics
Related News:- Lantheus Strengthens its Alzheimer’s Disease Pipeline Through the Acquisition of Meilleur Technologies
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
